Free tool
Stocks above their 200-day average
We cover 50 companies trading above their own 200-day average. The median market value in the group is $48.04B. Across the group, the median move over the past trading day is +1.25%. 100% of the 50 with a 200-day average trade above it. Price change over the past year runs from −4.6% to +73.9% across the middle 80 percent of the group, with a median of +21.2%.
Other lists in this group
Table
50 of 10,735 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| LLY.DE | Eli Lilly and Company | $1.07T | Mega cap | +73.55% |
| JNJ.DE | Johnson & Johnson | $651.71B | Mega cap | +58.93% |
| 4AB.DE | AbbVie Inc. | $471.29B | Mega cap | +32.34% |
| 6MK.DE | Merck & Co., Inc. | $379.64B | Mega cap | +91.49% |
| RHO.DE | Roche Holding AG | $370.84B | Mega cap | +41.42% |
| NOT.DE | Novartis AG | $300.14B | Mega cap | +28.89% |
| AMG.DE | Amgen Inc. | $237.76B | Mega cap | +60.12% |
| TN8.DE | Thermo Fisher Scientific Inc. | $234.00B | Mega cap | +29.67% |
| NVO.WA | Novo Nordisk A/S | $212.23B | Mega cap | −9.22% |
| NOVO-B.CO | Novo Nordisk A/S | $210.20B | Mega cap | −11.26% |
| NOV.DE | Novo Nordisk A/S | $209.27B | Mega cap | +15.22% |
| ABL.DE | Abbott Laboratories | $200.44B | Mega cap | −10.02% |
| GIS.DE | Gilead Sciences, Inc. | $184.35B | Large cap | +33.64% |
| PFE.DE | Pfizer Inc. | $161.11B | Large cap | +22.96% |
| DAP.DE | Danaher Corporation | $151.59B | Large cap | +6.90% |
| VX1.DE | Vertex Pharmaceuticals Incorporated | $139.82B | Large cap | +41.64% |
| BRM.DE | Bristol-Myers Squibb Company | $137.92B | Large cap | +50.84% |
| 2M6.DE | Medtronic plc | $117.57B | Large cap | +2.65% |
| MRK.DE | Merck KGaA | $70.28B | Large cap | +32.17% |
| 0QF.DE | Moderna, Inc. | $59.07B | Large cap | +550.51% |
| BAYN.DE | Bayer Aktiengesellschaft | $56.25B | Large cap | +76.91% |
| BAY.WA | Bayer Aktiengesellschaft | $55.90B | Large cap | +76.59% |
| EWL.DE | Edwards Lifesciences Corporation | $52.39B | Large cap | +11.65% |
| BOX.DE | Becton, Dickinson and Company | $51.84B | Large cap | +1.73% |
| SHL.DE | Siemens Healthineers AG | $51.23B | Large cap | −14.18% |
| H6D0.DE | Haleon plc | $44.85B | Large cap | +5.39% |
| HLN.L | Haleon plc | $44.62B | Large cap | +2.68% |
| QTS.DE | IQVIA Holdings Inc. | $43.01B | Large cap | −4.04% |
| VEE.DE | Veeva Systems Inc. | $40.02B | Large cap | +13.43% |
| ILU.DE | Illumina, Inc. | $34.08B | Large cap | +129.80% |
| DC4.DE | DexCom, Inc. | $33.35B | Large cap | +21.06% |
| IDP.DE | Biogen Inc. | $32.39B | Large cap | +65.32% |
| FRE.DE | Fresenius SE & Co. KGaA | $30.43B | Large cap | +1.64% |
| 22UA.DE | BioNTech SE | $28.28B | Large cap | +14.09% |
| MTO.DE | Mettler-Toledo International Inc. | $27.92B | Large cap | +13.15% |
| DIM.PA | Sartorius Stedim Biotech S.A. | $21.78B | Large cap | +11.64% |
| 56S1.DE | Sartorius Stedim Biotech S.A. | $21.77B | Large cap | +11.32% |
| GMAB.CO | Genmab A/S | $20.69B | Large cap | +36.19% |
| GE9.DE | Genmab A/S | $20.65B | Large cap | −11.12% |
| SRT3.DE | Sartorius Aktiengesellschaft | $19.68B | Large cap | +25.88% |
| VIA.DE | Viatris Inc. | $19.41B | Large cap | +67.32% |
| SOBI.ST | Swedish Orphan Biovitrum AB (publ) | $16.99B | Large cap | +61.26% |
| IPN.PA | Ipsen S.A. | $15.97B | Large cap | +40.80% |
| SRT.DE | Sartorius Aktiengesellschaft | $15.54B | Large cap | +21.79% |
| ESF0.DE | Eurofins Scientific SE | $14.67B | Large cap | +12.65% |
| ERF.PA | Eurofins Scientific SE | $14.64B | Large cap | +15.60% |
| ORNBV.HE | Orion Oyj | $13.16B | Large cap | +21.01% |
| ORNAV.HE | Orion Oyj | $13.11B | Large cap | +21.27% |
| FME.DE | Fresenius Medical Care AG | $12.64B | Large cap | −2.61% |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | $12.57B | Large cap | +1.80% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.